---
title: "BiomX Inc. 1Q 2026: Net income $(19.14M), EPS $(7.38) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287120250.md"
description: "BiomX Inc. reported a net loss of $19.14M for Q1 2026, up from $7.66M in Q1 2025, as it shifts focus from biopharma to defense technology. The company acquired Zorronet and a 60% stake in DFSL, launching a new unit, X Security. Revenue contributions from these acquisitions are expected starting Q2 2026, with active projects underway with major clients."
datetime: "2026-05-20T21:01:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287120250.md)
  - [en](https://longbridge.com/en/news/287120250.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287120250.md)
---

# BiomX Inc. 1Q 2026: Net income $(19.14M), EPS $(7.38) — 10-Q Summary

BiomX Inc. reported results for the first quarter of 2026 showing a larger net loss versus the year-ago quarter as the company shifts its strategy and begins integrating recent defense-technology acquisitions.

**Financial Highlights**

-   Net income: $(19.14M) for Q1 2026, versus $(7.66M) in Q1 2025.
-   Diluted EPS: $(7.38) for Q1 2026, versus $(6.27) in Q1 2025.

**Business Highlights**

-   Strategy shift: BiomX pivoted from biopharma to defense and security technology, acquiring Zorronet and a 60% stake in DFSL and forming a new unit, X Security.
-   Product momentum: DFSL’s LADAR and Zorronet’s AI platforms are positioned for deployments in counter-UAS, perimeter security and command-and-control video analytics.
-   Operational rollout: Management expects DFSL and Zorronet to begin contributing revenue and cash flow starting in Q2 2026; X Security is funded for 2026 operations.
-   Customer traction: Zorronet has active pilots and projects with Elbit, Rafael, IDF bases, and distribution agreements for stadium and UAE deployments.
-   R&D/IP: The company retains the APT legacy patent portfolio and related grants and is exploring commercialization, partnerships or out-licensing for remaining biotech assets.

Original SEC Filing: BiomX Inc. \[ PHGE \] - 10-Q - May. 20, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PHGE.US](https://longbridge.com/en/quote/PHGE.US.md)
- [DFNS.US](https://longbridge.com/en/quote/DFNS.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [ESLT.US](https://longbridge.com/en/quote/ESLT.US.md)

## Related News & Research

- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md)
- [Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery](https://longbridge.com/en/news/287100303.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)